Ribavirin: Biochemistry, Clinical Applications and Potential Side Effects

Joris Buskirk (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$78.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Ribavirin has been studied for over 20 years as a potential therapy against a number of RNA and DNA viruses. It is well known that Ribavirin in combination with Interferon is a key antiviral component in the treatment of Hepatitis C virus infection. In this book, the authors discuss the biochemistry, clinical applications and potential side effects of Ribavirin.

Topics include optimizing Ribavirin use for the treatment of Hepatitis C; Ribavirin and its great potential in infectious diseases; the antiviral actions of Ribavirin; a novel prediction method for the responsiveness of Hepatitis C patients to drug treatment; and Ribavirin’s intolerable cough during HCV combination therapy which can be overcome by replacement with Nitazoxanide. (Imprint: Nova Biomedical )

Preface pp.vii-xii

Optimizing Ribavirin Use for the Treatment of Hepatitis C
(Melissa Palmer, NYU Langone, and Kadmon Corporation, New York, NY, USA)pp.-1-36

Ribavirin and its Great Potentials in Infectious Diseases
(Gamal Esmat, Mohamed El Kassas, Tamer Elbaz, Maissa El Raziky, Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, and others)pp.37-58

Antiviral Actions of Ribavirin
(Inés Yeste-Gomez, Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain)pp.59-78

A Novel Prediction Method for the Responsiveness of Hepatitis C Patients to Drug Treatment
(Shigeru Takasaki, Toyo University, Izumino, Ora-gun Itakuracho, Gunma, Japan)pp.79-92

Ribavirin Intolerable Cough during HCV Combination Therapy can be Overcome by Nitazoxanide Replacement
(Mohamed H. Emara, Salem Y. Mohamed, Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt, and others)pp93-100

Index pp.101-108

You have not viewed any product yet.